Catalyst Wire Dossier Catalyst Wire Dossier

Daratumumab SC (Darzalex Faspro)

daratumumab · Janssen Biotech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Daratumumab SC (Darzalex Faspro), covering 2023-03-20 to 2023-03-20. Get the full timeline:

Most recent: Clinical Trial Update: INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

See pricing